Activity and safety of metronomic cyclophosphamide in the modern era of metastatic castration-resistant prostate cancer-Reference-Cited by-同舟云学术

Activity and safety of metronomic cyclophosphamide in the modern era of metastatic castration-resistant prostate cancer

Published:2019-04 Issue:10 Volume:15 Page:1115-1123
ISSN:1479-6694
Container-title:Future Oncology
language:en
Short-container-title:Future Oncology

Author:

Caffo Orazio¹,Facchini Gaetano²,Biasco Elisa³,Ferraù Francesco⁴,Morelli Franco⁵,Donini Maddalena⁶,Buttigliero Consuelo⁷,Calvani Nicola⁸,Guida Annalisa⁹,Chiuri Vincenzo Emanuele¹⁰,Basso Umberto¹¹,Mucciarini Claudia¹²,Conteduca Vincenza¹³,Rossetti Sabrina²,Veccia Antonello¹⁴,Maines Francesca¹⁴,Kinspergher Stefania¹⁴,De Giorgi Ugo¹³

Affiliation:

1. Medical Oncology Department, Santa Chiara Hospital, Largo Medaglie d’Oro, 38122 Trento, Italy

2. Departmental Unit of Clinical & Experimental Uro-Andrologic Oncology, Istituto Nazionale Tumori, IRCCS, Fondazione G Pascale, Via Mariano Semmola 52, 80131 Naples, Italy

3. Oncology Unit 2, University Hospital, Via Paradisa 2, 56124 Pisa, Italy

4. Medical Oncology Department, San Vincenzo Hospital, Via Sirina, 98039 Taormina, Italy

5. Medical Oncology Department, Casa Sollievo della Sofferenza, Viale Cappuccini 1, 71013 San Giovanni Rotondo, Italy

6. Medical Oncology Department, General Hospital, Viale Concordia, 26100 Cremona, Italy

7. Medical Oncology Department, University of Torino, San Luigi Hospital, Regione Gonzole 10, 10043 Orbassano, Italy

8. Medical Oncology Division & Breast Unit, Antonio Perrino Hospital, 72100 Brindisi, Italy

9. Medical Oncology Division, Azienda Ospedaliero Universitaria, Policlinico di Modena, 41100 Modena, Italy

10. Medical Oncology Unit, Vito Fazzi Hospital, 73100 Lecce, Italy

11. Medical Oncology Unit 1, Istituto Oncologico Veneto IOV, IRCCS, 35128 Padua, Italy

12. Medical Oncology Department, General Hospital, 41012 Carpi, Italy

13. Medical Oncology Department, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, 47014 Meldola, Italy

14. Medical Oncology Department, Santa Chiara Hospital, Largo Medaglie d'Oro, 38122 Trento, Italy

Abstract

Aim: To evaluate activity of metronomic cyclophosphamide (mCTX) in heavily pretreated metastatic castration-resistant prostate cancer (mCRPC) patients. Patients & methods: We retrospectively evaluated a consecutive series of 74 mCRPC patients treated with at least one new agent after docetaxel failure, who received once-daily oral mCTX treatment at a fixed dose of 50 mg. Results: The treatment was well tolerated. Sixteen percent of the patients experienced a major biochemical response. Median progression-free survival was 4.0 months, and median overall survival was 8.1 months. Conclusions: In the modern context of mCRPC, mCTX may represent a valuable and inexpensive alternative to new agents, which have shown similar activity in heavily pretreated patients.

Publisher

Future Medicine Ltd

Subject

Cancer Research,Oncology,General Medicine

Link

https://www.futuremedicine.com/doi/pdf/10.2217/fon-2018-0715

Reference38 articles.

1. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.

2. Phase II study of the oral cyclophosphamide and oral etoposide combination in hormone-refractory prostate carcinoma patients

3. Oral estramustine and cyclophosphamide in patients with metastatic hormone refractory prostate carcinoma

4. Oral Combination of Cyclophosphamide, Uracil plus Tegafur and Estramustine for Hormone-Refractory Prostate Cancer

5. Phase II trial of oral cyclophosphamide, prednisone, and diethylstilbestrol for androgen-independent prostate carcinoma

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety of metronomic cyclophosphamide combined with abiraterone and dexamethasone in heavily pretreated metastatic castration-resistant prostate cancer: A retrospective, real-world study;Asian Journal of Surgery;2024-08

2. Optimizing cancer therapy: a review of the multifaceted effects of metronomic chemotherapy;Frontiers in Cell and Developmental Biology;2024-05-15

3. Metronomic cyclophosphamide for bone marrow carcinomatosis in metastatic castration-resistant prostate cancer;Journal of Cancer Research and Clinical Oncology;2024-02-08

4. Therapy With Metronomic Cyclophosphamide (mCyc) for Previously-Treated Metastatic Castrate-Resistant Prostate Cancer (mCRPC);Clinical Genitourinary Cancer;2023-11

5. Activity and safety of KEES - an oral multi-drug chemo-hormonal metronomic combination regimen in metastatic castration-resistant prostate cancer;BMC Cancer;2023-04-04